NORTHAMPTON, MA / ACCESSWIRE / September 27, 2022 / In 2021, Quest labs continued to work with the Centers for Disease Control and Prevention (CDC) on genomic sequencing of SARS-CoV-2, the virus that causes COVID-19. The goal of the collaboration is to aid the CDC in conducting a large-scale survey of the SARS-CoV-2 virus to identify novel mutations, providing insights on the patterns of transmission and prevalence of these mutations in the US. "Public and private collaboration is essential to mobilizing an effective response to COVID-19." Jay G. Wohlgemuth, MD Chief Medical Officer, Senior Vice President, Research & Development Quest''s large-scale longitudinal genomic survey of the virus uses a random set of samples collected from Quest labs across the US. Quest sequences the virus genome in random, deidentified samples that test positive during molecular diagnostic COVID-19 testing for clinicians, providing the CDC with whole viral sequences. These data are combined with the results of other data provided to the CDC by national, state, academic, and commercial labs, helping to meet the CDC survey''s aims.
Quest Diagnostics Incorporated found using ticker (DGX) now have 14 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 160 and 129 with a mean TP of 144.5. Now with the previous closing price of 122.35 this would indicate that there is a potential upside of 18.1%. The 50 day MA is 131.67 and the 200 moving average now moves to 138.54. The market capitalisation for the company is $14,366m. Visit the company website at: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $16,967m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
SECAUCUS, N.J., Sept. 27, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world''s leading provider of diagnostic information services, announced that it will report third quarter 2022 financial results on Thursday, October 20, 2022, before the market opens. It will…
U.S. stocks have continued to slip as Wall Street prepares for another rate hike from the Federal Reserve. After wobbling between small gains and losses throughout the trading session, the S&P 500 closed higher 0.7% on Monday. The benchmark stock index was coming off one of its worst weeks of the year, when it fell nearly 5%. The reality is it has been a volatile summer of trading. The stock market rally proved short-lived as investors lost hope that the economy would look better in the coming months. One driver for the grim mood was last week’s Consumer Price Index ( CPI ), which showed inflation was higher than expected. Consumer prices rose 8.3% year-over-year in August, down from 8.5% over in July but above the 8.1% economists expected. We talked more about this and the effect this will have on the Fed in last Tuesday’s Market 360 issue . It’s important that you begin adjusting your portfolio to make sure that you’re invested in fundamentally superior companies – companies with strong sales and earnings growth and positive outlooks – as these will be the go-to names for investors once third-quarter earnings season gets underway.
Quest Diagnostics has been in my “Healthy Dividends” portfolio thanks to a safe dividend and long-term growth prospects. Click to read why the stock is a buy.
One sells a treatment. The other sells a diagnostic test.
The NASDAQ Composite ground higher in choppy trading on Wednesday as investors tried to find their footing after the biggest one-day drop in more than two years. The Dow Jones Industrials gained 30.12 points Wednesday to 31,135.09 The S&P 500 piled on 13.32 points to 3,946.01. The NASDAQ Composite rocketed 86.1 points to 11,719.68. Moderna was one of the top performers in the NASDAQ, jumping more than 6%. Tesla rose 3.6%, and Apple tacked on 1%. Wednesday’s late day 52-week lows in the S&P 500 included Intel, which fell to the lowest since February 2016. Other stocks hitting 52-week lows included Walgreens Boots Alliance lowest since Nov. 2020 Capital One (Jan. 2021) Quest Diagnostics (March 2021) The Dow sank more than 1,200 points Tuesday, or nearly 4%, while the S&P 500 lost 4.3%. The NASDAQ Composite dropped 5.2%. It was the biggest one-day slide for all three averages since June 2020. The market moves came after August’s consumer price index report showed headline inflation rose 0.1% on a monthly basis despite a drop in gas prices.
Equities in Canada’s largest centre ebbed and flowed on Wednesday, before settling in higher country. This, as Wall Street stabilized following a rout in the previous session on rate hike fears, while a bounce in oil prices pushed energy stocks higher. The TSX Composite hung onto gains of 80.74 points to close Wednesday at 19,726.14. The Canadian dollar ditched 0.03 cents to 75.94 cents. Energy stocks led the gainers, as Secure Energy vaulted 38 cents, or 6.8%, to $5.96. Cenovus Energy hiked $1.18, or 4.9%, to $25.49. In health-care, Bausch Health Companies sprinted 55 cents, or 5.7%, to $10.25, while Aurora Cannabis added three cents, or 1.5%, to $2.00. In tech issues, Converge jumped 27 cents, or 4.6%, to $6.13, while Softchoice added 76 cents, or 4.1%, to $19.47. Units of Allied Properties REIT helped anchor real-estate issues down, losing 70 cents, or 2.2%, to $31.12, while SmartCentres REIT lost 58 cents, or 2%, to $27.86. In communications, Corus Entertainment dipped 20 cents, or 7%, to $2.66, while BCE fell $1.36, or 2.2%, to $61.14.
Quest Diagnostics should see profits fall somewhat as Covid wanes, but there are other upside risks in this low P/E stock. Click here to read more about DGX stock.
SECAUCUS, N.J., Sept. 8, 2022 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world''s leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference. Jim Davis, CEO-elect, and Sam…
Quest Diagnostics Incorporated found using ticker (DGX) now have 14 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 160 and 129 and has a mean target at 144.86. With the stocks previous close at 127.1 this is indicating there is a potential upside of 14.0%. The 50 day MA is 135.35 and the 200 day MA is 141.05. The market capitalisation for the company is $14,766m. Company Website: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $16,829m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
With the latest outbreak now reported in all 50 states per ABC News , investors may want to consider the top monkeypox stocks to buy right now. From an investment perspective, this latest health threat poses powerful catalysts. For one thing, the risks are real. According to the New England Journal of Medicine , monkeypox is a zoonotic orthopox DNA virus related to the virus that causes smallpox . While cases have circulated for decades, research has been neglected and underfunded. Not only does infection cause pain, it can also lead to organ injury. Therefore, the framework for the top monkeypox stocks to buy right now commands sober attention. Additionally, monkeypox symptoms create anxieties and distress. Therefore, significant incentives undergird these top monkeypox stocks to buy right now. DGX Quest Diagnostics $128.83 BVNRY Bavarian Nordic $16.15 EBS Emergent BioSolutions $27.28 Quest Diagnostics (DGX) Source: Sundry Photography / Shutterstock.com Arguably one of the more conservative names among the top monkeypox stocks to buy, Quest Diagnostics (NYSE: DGX ) offers clinical assessments.
NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO ) , welcomes Sharon Robins as the Company''s Senior Director of Laboratory & Hospital Sales for the Product''s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (annualized run rate), Ms. Robins will be tasked with managing that relationship and ensuring its success. Coming from Qiagen, a market leader in the diagnostic reagents field, Ms. Robins brings with her a strong background in multiple leadership positions in diagnostic product sales. During her tenure at Qiagen she was responsible for over $100M in annual revenues. Sharon has a strong background in diagnostics distribution, previously holding senior sales positions at Quest Diagnostics, ThermoFisher, and Life Technologies. In those roles she led teams and was responsible for triple-digit million-dollar revenues. "We are extremely fortunate to have attracted an executive of Sharon''s caliber to our company.
Quest Diagnostics Incorporated with ticker code (DGX) have now 14 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 160 and 129 with the average target price sitting at 144.86. Now with the previous closing price of 135.48 this is indicating there is a potential upside of 6.9%. The day 50 moving average is 135.34 and the 200 moving average now moves to 141.4. The company has a market capitalisation of $15,798m. Company Website: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $16,892m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
https://www.investing.com/news/pro/quest-diagnostics-pt-raised-to-165-at-argus-432SI-2875001
Quest Diagnostics (DGX) announced on Wednesday the launch of a new obstetrics laboratory test panel to enable physicians to screen all eligible pregnant people for hepatitis C with…
(RTTNews) - Quest Diagnostics (DGX) announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people for hepatitis C with other laboratory tests typically ordered during early pregnancy. The company noted that the new test panel follows a Quest Diagnostics Health Trends study…
Quest Diagnostics (NYSE:DGX) declares $0.66/share quarterly dividend, in line with previous.Forward yield 1.9%Payable Oct. 19; for shareholders of record Oct. 4; ex-div Oct.
SECAUCUS, N.J., Aug. 10, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world''s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on October 19, 2022 to shareholders of…
The White House has declared monkeypox a public health emergency . Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the alarm. With the Joe Biden administration finally issuing this decree, though, public health officials have more flexibility to take action. The Washington Post reports that a second declaration is also under consideration. Under it, public health officials could “expedite medical countermeasures, such as potential treatments and vaccines, without going through full-fledged federal reviews.” Details are still emerging but one thing is clear; the U.S. is about to see a new focus on monkeypox vaccines. This means an influx in demand for the companies that produce them. Investors are already assessing the best monkeypox stocks. The Covid-19 pandemic isn’t over but the U.S. is already entering a new vaccine boom. But the delayed vaccine rollout continues to raise questions. CNN reports that the U.S. delayed a large-scale vaccine order out of fear of the shots expiring before being administered.
IRVING, Texas, Aug. 4, 2022 /PRNewswire/ -- Better healthcare among America''s large and growing Hispanic community is receiving an important, new level of support from Quest Diagnostics, the world''s leading provider of diagnostic information services, through the launch of a multi-faceted…
According to a study conducted by Quest Diagnostics Inc (NYSE: DGX ), drug use among American employees, as measured by the percentage of employees who tested positive in urine drug tests, hit a 14-year high in 2018, reaching 4.4 percent. Cannabis continues to be the most popular substance, with 2.8 percent of all employees tested showing positive results. The news led addiction experts at the American Addiction Centers to wonder about the impact this might have on pre-employment drug testing in professionals. Seeking for an answer, they conducted an analysis of job postings on the popular website Glassdoor. They were trying to find out what types of jobs are most likely to include requirements for drug tests, and regular drug screening. Overall, remarkably few jobs disclose that they require drug testing before confirming employment, or during employment. On average, only 1.47 percent of job postings in the U.S. mention that they require pre-employment drug tests. See also:
Quest Diagnostics Incorporated (NYSE:NYSE:DGX) Q2 2022 Earnings Conference Call July 21, 2022 08:30 ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve…
https://www.investing.com/news/pro/quest-diagnostics-pt-lowered-to-142-at-cfra-432SI-2851060
Quest Diagnostics Inc. (NYSE: DGX) Q2 2022 earnings call dated Jul. 21, 2022
Companies Reporting Before The Bell • SAP (NYSE: SAP ) is projected to report quarterly earnings at $1.15 per share on revenue of $7.56 billion. • Webster Finl (NYSE: WBS ) is likely to report earnings for its second quarter. • Champions Oncology (NASDAQ: CSBR ) is projected to report quarterly earnings at $0.02 per share on revenue of $12.72 million. • Atlantic Union Bankshares (NASDAQ: AUB ) is estimated to report quarterly earnings at $0.70 per share on revenue of $172.65 million. • OFG Bancorp (NYSE: OFG ) is likely to report quarterly earnings at $0.74 per share on revenue of $111.55 million. • Home BancShares (NYSE: HOMB ) is likely to report quarterly earnings at $0.34 per share on revenue of $227.32 million. • Heritage Financial (NASDAQ: HFWA ) is projected to report quarterly earnings at $0.45 per share on revenue of $56.89 million. • KeyCorp (NYSE: KEY ) is expected to report quarterly earnings at $0.52 per share on revenue of $1.76 billion. • Tractor Supply (NASDAQ: TSCO ) is likely to report quarterly earnings at $3.
Quest Diagnostics (DGX) is scheduled to announce Q2 earnings results on Thursday, July 21st, before market open.The consensus EPS Estimate is $2.26 (-28.9% Y/Y) and the consensus Revenue…
Quest Diagnostics (NYSE: DGX ) is set to give its latest quarterly earnings report on Thursday, 2022-07-21. Here''s what investors need to know before the announcement. Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.20. Quest Diagnostics bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
https://www.investing.com/news/pro/quest-diagnostics-pt-lowered-to-150-at-bofa-securities-432SI-2849750
Rite Aid (RAD) is collaborating with Quest Diagnostics (DCX) to provide COVID-19 PCR testing at more than 2,350 stores.
New York, 2022-Jul-18 — /EPR Network/ — Global Clinical Laboratory Service Market report from Global Insight Services is the single authoritative source of intelligence on [read full press release…]
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company''s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: eFFECTOR Therapeutics (NASDAQ: EFTR ) - P/E: 1.81 Quest Diagnostics (NYSE: Full story available on Benzinga.com
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, recently announced the launch of its lab-developed molecular diagnostic test for the monkeypox virus. In a release, the company said, "The polymerase chain reaction (PCR) test is the first commercially available test to be developed and made available by a national laboratory provider for helping in the qualitative detection and differentiation of monkeypox virus DNA from other non-variola orthopoxviruses." Quest Diagnostics expects to conduct around 30,000 monkeypox virus tests a week by the end of July. The company can also enhance its capacity for monkeypox testing across other laboratories in its national network if the demand is too high.
Starting today, Quest Diagnostics will begin testing for monkeypox.
Quest Diagnostics (NYSE: DGX ) has announced the nationwide availability of a lab-developed, automated molecular diagnostic test to identify if a person is infected with monkeypox. What Happened: The Secaucus, New Jersey-headquartered company is expecting to have the capacity to conduct approximately 30,000 monkeypox virus tests a week by the end of July. Based on demand, Quest said it will expand the capacity for its monkeypox testing to other advanced laboratories in its national network. Quest is also validating the orthopoxvirus test from the U.S. Centers for Disease Control and Prevention, with the goal of making it available … Full story available on Benzinga.com
Quest Diagnostics (DGX) on Wednesday announced the availability of its lab-developed molecular diagnostic test to help diagnose infection with the monkeypox virus, and plans to launch…
Quest Diagnostics (DGX) on Thursday said it was partnering with the Centers for Disease Control and Prevention ((CDC)) to extend access to COVID-19 testing in U.S
S&P 500 stocks have been a mixed bag at best this year. During the week of June 21, I think the market began to accept the idea that a ” soft landing” by the economy is much more likely than a “hard landing.” Of course, the market rallied during the week. As further evidence of the Street’s renewed optimism, Goldman Sachs economist Jan Hatzius, speaking on Bloomberg TV o n June 24, said that any recession would probably be “on the shallow end.” Even more bullish was RBC Capital Managing Director Gerard Cassidy, who told Bloomberg TV on June 24 that “as long as the job market stays strong, (U.S.) consumers will be in good shape.” 7 REITs to Buy for a Bear Market With the Street realizing that the economy is not going to crash, I believe that there are many good S&P 500 stocks to buy. Meanwhile, as Bloomberg TV’s Lisa Abramowicz pointed out on June 24, many market participants now think that Fed Chairman Jerome Powell will be less “hawkish” on inflation than the Street has generally believed in recent months.
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com''s offering. The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth. The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques. Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings.
With stocks down by double-digits year-to-date there are many bargains out there today among undervalued large-cap stocks. That’s not to say, however, that the market has reached a bottoming out point. With the Federal Reserve kicking its rate hike plans up a notch, equities may continue to slide lower, as the market absorbs higher rates. Not to mention, the high inflation that resulted in rates moving up, plus growing chances of a recession. Yet even if stocks have more room to move lower in the short-term, if you’re looking for long-term opportunities, it may be worthwhile to take a look at the many large-cap names now trading at low valuations. Although there are stocks that have moved lower for a reason, there are also plenty that have become oversold. With some names, investors are overreacting to negative developments. With others, the market is underestimating how long recent tailwinds will last. 7 Stocks to Buy That Could Make You a Millionaire The seven undervalued large-cap stocks listed below fall within these three categories.
The Biden administration said Wednesday that commercial laboratories would be allowed to conduct monkeypox tests as the U.S
Quest Diagnostics has the proven and admirable ability to make attractive returns from superb customers and markets. See why I rate DGX stock is a hold.
Quest Diagnostics Incorporated with ticker code (DGX) now have 14 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 185 and 129 and has a mean target at 151.86. Given that the stocks previous close was at 127.98 this is indicating there is a potential upside of 18.7%. The 50 day moving average now sits at 136.4 and the 200 day moving average is 144.03. The market cap for the company is $15,333m. Find out more information at: https://www.questdiagnostics.com [stock_market_widget type="chart" template="basic" color="green" assets="DGX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $18,193m based on the market concensus. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Dublin, June 16, 2022 (GLOBE NEWSWIRE) -- The "Endocrine Testing Product Market, by Product Type, by Technology, by Test Type, by Disease Indication, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com''s offering. Market players are engaged in launching new products for endocrine testing products, this is expected to increase the growth of the global endocrine testing products, over the forecast period. For instance, in July 2018, Ortho Clinical Diagnostics launched VITROS XT 7600 Integrated System, at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo, held in U.S. It has applications in cardiology, infectious diseases, and endocrinology. Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global endocrine testing products market, over the forecast period. For instance, in 2020, Hackensack Meridian Health, an integrated health care network in New Jersey, U.S. and Quest Diagnostics, entered into a partnership, in order to increase the quality and value of diagnostic services provided to patients and their doctors.
NEW YORK, NY / ACCESSWIRE / June 14, 2022 / Stevia Corp. (OTC PINK:STEV) ("Stevia Corp" or the "Company"), a healthcare company focused on the commercial development of products that support a healthy lifestyle announced today the appointment of …
https://www.investing.com/news/stock-market-news/illumina-falls-6-as-cfo-leaves-to-take-same-role-at-quest-diagnostics-432SI-2835496
In the last trading session, 0.89 million shares of the Quest Diagnostics Incorporated (NYSE:DGX) were traded, and its beta was 1.03. Most recently the company’s share price was $145.39, and it changed around $3.74 or 2.64% from the last close, which brings the market valuation of the company to $16.63B. DGX currently trades at a … Future Outlook And Stock Price Performance For Quest Diagnostics Incorporated (NYSE: DGX) Read More »
Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd. , Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated. Major players in the anatomical pathology equipment and consumables market are Epridea, F. Hoffmann-La Roche Ltd. , Danaher Corporation, Thermo Fisher Scientific, Sakura Finetek, Agilent Technologies, Danaher Corporation, Bio SB, BioGenex Laboratories, and Quest Diagnostics Incorporated.
SECAUCUS, N.J. , May 17, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX ), the world''s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on July 20, 2022 to shareholders of record of Quest Diagnostics common stock on July 6, 2022. Full story available on Benzinga.com
Adding defensive healthcare stocks can be a great way to ride out continued volatility in the market. AbbVie ( ABBV ): Investors are overreacting to this venerable big pharma company’s recent earnings report. Amgen ( AMGN ): An established biotech company with a high forward dividend yield (3.33%). Baxter International ( BAX ): A reasonably-priced medical products provider on track to deliver strong results. Quest Diagnostics ( DGX ): Focus will soon shift to the evergreen nature of its main testing business. Humana ( HUM ): Growing Medicare Advantage enrollments point to stability and growth for Humana. Merck ( MRK ): Still has room to move higher, despite recent post-earnings spike. Zoetis ( ZTS ): While regarded as a high-growth high-flier, Zoetis is inflation and recession-resistant. Uncertainty about the stock market and the overall economy continues to run high. It’s not too late to go defensive. A good way to do that is to focus your portfolio on dividend-paying defensive stocks.